News & Updates

What are the barriers to communication between pharmacists during transitions of care?

18 Jun 2023

Several barriers to communication exist between pharmacists during transitions of care (TOC) across healthcare settings, reports a US study.

What are the barriers to communication between pharmacists during transitions of care?

18 Jun 2023

Colon cancer survival with neoadjuvant chemo vs upfront surgery a toss-up

18 Jun 2023

In the treatment of patients with colon cancer, neoadjuvant chemotherapy does not appear to yield better survival benefit than standard upfront surgery, according to the results of the phase III NeoCol trial presented at ASCO 2023.

Colon cancer survival with neoadjuvant chemo vs upfront surgery a toss-up

18 Jun 2023

Low-dose atropine helps control childhood myopia progression

18 Jun 2023

The novel, preservative-free, low-dose atropine formulation NVK002 appears to be beneficial in the treatment of myopia progression in children when compared with placebo, according to the results of a phase III study.

Low-dose atropine helps control childhood myopia progression

18 Jun 2023

Is ursodeoxycholic acid beneficial in critically ill patients with sepsis?

17 Jun 2023

Critically ill patients with sepsis or septic shock who use ursodeoxycholic acid (UDCA) do not seem to experience improvement in shock severity and resolution, reveals a recent study. However, they have a higher chance of being extubated and not needing mechanical ventilation (MV) on the third day of admission to the intensive care unit (ICU).

Is ursodeoxycholic acid beneficial in critically ill patients with sepsis?

17 Jun 2023

Cumulative immunomodulator exposure may heighten risk of CIN2+ in IBD

16 Jun 2023

Among women with inflammatory bowel disease (IBD), those who have long-term immunomodulator exposure are at increased risk of high-grade cervical intraepithelial neoplasia and cervical cancer (CIN2+), according to a study.

Cumulative immunomodulator exposure may heighten risk of CIN2+ in IBD

16 Jun 2023

Atrial fibrillation patients use same anticoagulant after bleeding event

16 Jun 2023

A recent study has shown that the majority of patients with nonvalvular atrial fibrillation who have had a bleeding event resume anticoagulation therapy usually with the same drug class that they have been using.

Atrial fibrillation patients use same anticoagulant after bleeding event

16 Jun 2023

Odevixibat reduces bile acids, improves sleep, pruritus in Alagille syndrome

16 Jun 2023 by

Patients with Alagille syndrome (AS) may benefit from treatment with odevixibat, with the phase III ASSERT study showing that its use results in rapid, sustained, and highly significant improvements in pruritus, sleep quality, as well as decreases in bile acids (BAs). Odevixibat is also well tolerated.

Odevixibat reduces bile acids, improves sleep, pruritus in Alagille syndrome

16 Jun 2023

Thiazide plus potassium-sparing diuretics outdoes monotherapy in hypertension

16 Jun 2023

Use of thiazides with potassium-sparing (PS) diuretics results in greater blood pressure (BP)-lowering efficacy, as well as reduces hypokalaemia and hyperglycaemia, compared with thiazides alone, reports a recent study.

Thiazide plus potassium-sparing diuretics outdoes monotherapy in hypertension

16 Jun 2023

Ribociclib plus endocrine therapy: A win for early breast cancer?

16 Jun 2023 by

In the second interim efficacy analysis of the phase III NATALEE trial, a combination regimen comprising the CDK4/6 inhibitor ribociclib and endocrine therapy (ET) demonstrated favourable signals for the adjuvant treatment of stage II/III hormone receptor-positive, HER2-negative (HR+, HER2–) early breast cancer.

Ribociclib plus endocrine therapy: A win for early breast cancer?

16 Jun 2023

Original New Drug Application Approvals by US FDA (01-15 June 2023)

16 Jun 2023

New drug applications approved by US FDA as of 01-15 June 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (01-15 June 2023)

16 Jun 2023

News & Updates

Filter by Specialty:

Specialty:

What are the barriers to communication between pharmacists during transitions of care?

What are the barriers to communication between pharmacists during transitions of care?

Colon cancer survival with neoadjuvant chemo vs upfront surgery a toss-up

Colon cancer survival with neoadjuvant chemo vs upfront surgery a toss-up

Low-dose atropine helps control childhood myopia progression

Low-dose atropine helps control childhood myopia progression

Is ursodeoxycholic acid beneficial in critically ill patients with sepsis?

Is ursodeoxycholic acid beneficial in critically ill patients with sepsis?

Cumulative immunomodulator exposure may heighten risk of CIN2+ in IBD

Cumulative immunomodulator exposure may heighten risk of CIN2+ in IBD

Atrial fibrillation patients use same anticoagulant after bleeding event

Atrial fibrillation patients use same anticoagulant after bleeding event

Odevixibat reduces bile acids, improves sleep, pruritus in Alagille syndrome

Odevixibat reduces bile acids, improves sleep, pruritus in Alagille syndrome

Thiazide plus potassium-sparing diuretics outdoes monotherapy in hypertension

Thiazide plus potassium-sparing diuretics outdoes monotherapy in hypertension

Ribociclib plus endocrine therapy: A win for early breast cancer?

Ribociclib plus endocrine therapy: A win for early breast cancer?

Original New Drug Application Approvals by US FDA (01-15 June 2023)

Original New Drug Application Approvals by US FDA (01-15 June 2023)